Orphan Drug Designations:
Six-Year Trends and Strategic Insights
Orphan drug designation
Orphan Drug Designation (ODD) is granted to drugs developed for rare diseases. Because such treatments often have limited commercial potential, the Orphan Drug Act of 1983 encourages development by offering incentives. Developers can apply for ODD, and the FDA grants it if the eligibility criteria are met. Benefits include tax credits for clinical testing, waiver of FDA application fees, and seven years of market exclusivity after approval. The Act also established the Orphan Products Grants Program to support the development of products for rare diseases.
Orphan drug designations Over the Past Six Years (2020–2025)
The orphan drug designation trend over the past six years shows a generally fluctuating but relatively stable pattern, with no consistent upward or downward trajectory. The numbers moved between the low 20s and low 30s, reflecting periodic variation in rare disease pipeline activity rather than a steady expansion or decline.
Starting in 2020, designations were relatively high at 31 drugs, followed by a dip in 2021 (26 drugs) and a further decline in 2022 (20 drugs), marking the lowest point in the period. The trend rebounded in 2023 to 28 designations, suggesting renewed rare disease R&D momentum, before stabilising again in 2024 at 26 drugs. In 2025, the number slightly decreased to 23 designations, indicating a modest cooling after the 2023–2024 recovery phase.
Overall, the data suggest that orphan drug designations remain consistently active but cyclical, influenced by shifts in clinical pipelines, regulatory submissions, and the timing of rare disease programs reaching designation milestones.
Six-Year Trend in Orphan Drug Designations (2020–2025)
Fig 5: Orphan Drug Designation trends
A few notable 2025 orphan drug designation examples highlight the continued focus on high-need rare conditions:
- WASKYRA (Wiskott-Aldrich syndrome) – a gene-related pediatric immune disorder therapy.
- ITVISMA (spinal muscular atrophy) – targeting SMA, a severe neuromuscular genetic disease.
- ZEVASKYN (recessive dystrophic epidermolysis bullosa) – addressing a rare and severe skin fragility disorder.
- ENCELTO (MacTel type 2) – for a rare degenerative retinal vascular condition.
- PAPZIMEOS (recurrent respiratory papillomatosis) – a rare viral-driven airway disease.